Acorda Recognized with Legal Media Group 2015 Life Sciences Award
October 02 2015 - 6:01AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that its
legal team has been recognized with a Legal Media Group 2015 Life
Sciences Award as a “Hatch-Waxman Impact Case of the Year.” Acorda
received the award based on its initial district court victory
related to jurisdiction against the filer of an Abbreviated New
Drug Application (ANDA).
“We’re delighted by this recognition of our outstanding in-house
legal team, led by President, International and General Counsel
Jane Wasman and supported by expert external counsel, Kaye Scholer.
This award underscores our exceptional achievements in the area of
patent litigation,” said Ron Cohen, President and CEO of
Acorda.
Legal Media Group selected Acorda Therapeutics v Mylan
Pharmaceuticals from among all of the Hatch-Waxman cases pending in
the United States over the last year. The case concerned Mylan’s
motion to dismiss Acorda’s ANDA case against it. Acorda won the
motion based on fundamental jurisdictional issues; Mylan has
appealed. The decision in this case may set a precedent regarding
where brand companies can sue generics in pending and future ANDA
cases.
“We’re proud of the contribution we can make to the case law, as
defending legitimate intellectual property rights is critical to
the biotechnology industry’s ability to continue to invest in new,
innovative medicines,” said Jane Wasman, President, International
and General Counsel of Acorda.
The Acorda in-house Legal Department also was recognized by
Corporate Counsel in 2013 as one of the nation’s four “Best Legal
Departments” of the year.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. The
Company has one of the leading pipelines in the industry of novel
neurological therapies. Acorda is currently developing a number of
clinical and preclinical stage therapies. This pipeline addresses a
range of disorders including post-stroke walking deficits,
Parkinson’s disease, epilepsy, heart failure, MS and spinal cord
injury.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal
Spray, or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, Plumiaz, or any other products under
development; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain regulatory approval of or
to successfully market Fampyra outside of the U.S. and our
dependence on our collaboration partner Biogen in connection
therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses
needed for the commercialization of our products; and, failure to
comply with regulatory requirements could result in adverse action
by regulatory agencies.
These and other risks are described in greater detail
in Acorda Therapeutics' filings with the Securities
and Exchange Commission. Acorda may not actually achieve the goals
or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of
the date hereof, and Acorda disclaims any intent or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151002005126/en/
Acorda TherapeuticsJeff Macdonald, 914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2024 to May 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From May 2023 to May 2024